"Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment" was originally created and published by Clinical ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

In 2002, on the heels of the discovery that RNA interference existed in human cells, the usually reserved journal Science proclaimed RNAi the "breakthrough of the year." Here was a part of the ...

a phenomenon called RNA interference or RNAi. The apparently widespread nature of RNAi in eukaryotes, ranging from trypanosome to mouse, has sparked great interest from both applied and ...

Efficient RNA interference in Caenorhabditis elegans requires a distinct class of secondary short interfering RNA. Although many proteins involved in RNAi were initially studied in the context of ...

View full profile. Learn about our editorial policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...